DK3065761T3 - Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin - Google Patents

Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin Download PDF

Info

Publication number
DK3065761T3
DK3065761T3 DK14802544.8T DK14802544T DK3065761T3 DK 3065761 T3 DK3065761 T3 DK 3065761T3 DK 14802544 T DK14802544 T DK 14802544T DK 3065761 T3 DK3065761 T3 DK 3065761T3
Authority
DK
Denmark
Prior art keywords
eyes
eye
treating
procedure
vegf darpin
Prior art date
Application number
DK14802544.8T
Other languages
Danish (da)
English (en)
Inventor
Thomas Hohman
Janet Cheetham
Scott Whitcup
Erik Lippa
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK3065761T3 publication Critical patent/DK3065761T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK14802544.8T 2013-11-05 2014-11-04 Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin DK3065761T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US201462016620P 2014-06-24 2014-06-24
PCT/US2014/063951 WO2015069668A1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin

Publications (1)

Publication Number Publication Date
DK3065761T3 true DK3065761T3 (da) 2020-02-17

Family

ID=51947485

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14802544.8T DK3065761T3 (da) 2013-11-05 2014-11-04 Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin

Country Status (14)

Country Link
US (4) US20150126458A1 (enExample)
EP (2) EP3628324A1 (enExample)
JP (3) JP2016536369A (enExample)
KR (1) KR20160070164A (enExample)
CN (1) CN105960247A (enExample)
AU (2) AU2014346921A1 (enExample)
CA (1) CA2927012A1 (enExample)
DK (1) DK3065761T3 (enExample)
ES (1) ES2773317T3 (enExample)
HU (1) HUE047910T2 (enExample)
PL (1) PL3065761T3 (enExample)
PT (1) PT3065761T (enExample)
TW (1) TWI729970B (enExample)
WO (1) WO2015069668A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
PL2846836T3 (pl) 2012-05-07 2020-01-31 Allergan, Inc. Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度vegf受容体融合タンパク質を含む製剤
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
JP7611173B2 (ja) * 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えfap結合タンパク質及びそれらの使用
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
CN116710135A (zh) * 2020-10-07 2023-09-05 6线生物技术公司 用于治疗眼部疾病的方法和试剂
JP2023545737A (ja) 2020-10-08 2023-10-31 ノータル ビジョン リミテッド Octガイド治療
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK2402754T4 (da) 2006-03-06 2023-08-28 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelser deraf
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび/またはインビトロ安定性が増大した生物学的に活性なタンパク質
MX359570B (es) * 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PL2846836T3 (pl) * 2012-05-07 2020-01-31 Allergan, Inc. Sposób leczenia amd u pacjentów opornych na terapię anty- vegf

Also Published As

Publication number Publication date
EP3065761A1 (en) 2016-09-14
ES2773317T3 (es) 2020-07-10
AU2020202968A1 (en) 2020-05-21
JP2020169191A (ja) 2020-10-15
AU2014346921A1 (en) 2016-06-02
JP2022107628A (ja) 2022-07-22
US20210008158A1 (en) 2021-01-14
CA2927012A1 (en) 2015-05-14
US20170157207A1 (en) 2017-06-08
HUE047910T2 (hu) 2020-05-28
CN105960247A (zh) 2016-09-21
PL3065761T3 (pl) 2020-05-18
JP2016536369A (ja) 2016-11-24
WO2015069668A1 (en) 2015-05-14
TW201609125A (zh) 2016-03-16
TWI729970B (zh) 2021-06-11
PT3065761T (pt) 2020-02-21
US20150126458A1 (en) 2015-05-07
EP3628324A1 (en) 2020-04-01
EP3065761B1 (en) 2020-01-08
KR20160070164A (ko) 2016-06-17
US20220175881A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating ocular diseases
IL265996A (en) Therapeutic laser with reflex mirror
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
IL247738B (en) Handling glare in eye tracking
LT3397321T (lt) Automatinis injektorius su temperatūros reguliatoriumi
DK3003309T3 (da) Behandling af cancer med PI3-kinase-isoform modulatorer
DK3397324T3 (da) Autoinjektor med patronfastholdelsessystem
EP3134031C0 (en) INTRAOCULAR LENS
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
EP2976042A4 (en) AKKOMMODATIVE INTRAOCULAR LENS
SG11201801776UA (en) Intraocular lens injector
PL3065761T3 (pl) Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
SG11201801775TA (en) Intraocular lens injector
PL3291766T3 (pl) Soczewka wewnątrzgałkowa o wysokiej rozdzielczości i rozszerzonej głębi ostrości
DK2958978T3 (da) Fremgangsmåde og anordning til fremstilling af brændstof ud af biomasse
EP3005981A4 (en) IMPLANTABLE LENS FOR CORRECTION OF SHORT-TERM AND MANUFACTURING METHOD THEREFOR
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
DK3198361T3 (da) Hardwarestyrede effektdomæner med automatisk tænd-anmodning
IL254825A0 (en) Methods of treatment with taselisib
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3049100T3 (da) Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser
EP2990012A4 (en) ASPHARIC INTRAOCULAR LENS